MD Anderson Sep 9, 2022 Virogin Biotech, MD Anderson Ink Collaboration to Study Oncolytic Viruses Aug 23, 2022 Erasca, MD Anderson Cancer Center Partner to Study ERK, SHP2 Inhibitors Aug 10, 2022 VolitionRx, MD Anderson Cancer Center Partner to Study Cancer Patients With Sepsis Jul 25, 2022 Delphi Diagnostics SET2,3 Test Clarifies Therapy Options for Certain Breast Cancer Patients Premium Jul 21, 2022 MD Anderson, Obsidian Therapeutics to Launch First-In-Human Trial of Engineered TILs for Melanoma Jul 14, 2022 Synthetic Control Arms Finding Stronger Footing in Precision Oncology Trials, Regulatory Submissions Premium Jun 24, 2022 MD Anderson, Turning Point Therapeutics Partner to Study Repotrectinib, Elzovantinib Jun 23, 2022 MD Anderson Study Explains Differing BRAF/MEK Treatment Responses in Male, Female Melanoma Patients Premium Jun 15, 2022 Estimated Total Tumor mRNA Predicts Cancer Outcomes, Study Shows Premium Jun 2, 2022 Stand Up To Cancer, Mirati Fund Research into KRAS G12C Inhibitor Resistance Premium May 2, 2022 Alaunos Therapeutics Begins Study of Autologous Cell Therapy Using Non-Viral Gene Transfer Apr 10, 2022 AACR Data Show Donor NK Cells Plus Bispecific Antibody Could Benefit CD30-Positive Lymphoma Patients Premium Mar 22, 2022 Large Study Identifies Potential Therapeutic Targets for MDS Patients who Fail Initial Treatment Premium Mar 8, 2022 Ayala Begins Trial to Explore AL101 Activity in Notch-Activated Cancer of Secretory Glands Jan 18, 2022 Eisbach Bio, MD Anderson Partner to Identify Synthetic Lethal Drug Targets Nov 4, 2021 Repare Therapeutics' RP-3500 Shows Potential of ATR Inhibitors in Precision Oncology Premium Sep 30, 2021 MD Anderson, Rare Cancer Research Foundation Team Up on Tissue Collection Effort Sep 28, 2021 MD Anderson, BostonGene Ink Collaboration to Develop Cancer Diagnostics Sep 19, 2021 MD Anderson Researchers Explore Neoadjuvant Keytruda in MSI-high Solid Tumors Sep 14, 2021 MD Anderson, Snipr Biome Partner to Reduce Immunotherapy Toxicity With Microbiome CRISPR Approach Load More Breaking News In Brief This Week: Gilead Sciences, Arcus Biosciences, Verismo Therapeutics, Caris Life Sciences Pyxis Oncology Gets FDA Permission to Start Phase I Trials of Anti-EDB Drug, Immunotherapy FDA Approves Rigel Pharmaceuticals' Rezlidhia for IDH1-Mutant AML Sofie Biosciences to Begin Trial of Fluorine-Labeled PET Diagnostic Imaging Agent for GI Cancers Study Unearths Features Found in Long-Term Survivors of Advanced Ovarian Cancer Carrick Therapeutics Receives $35M Investment From Pfizer; Raises $25M in Series C Funding Round
